Epidemiology of human immunodeficiency virus-associated opportunistic infections in the United States in the era of highly active antiretroviral therapy.

The incidence of nearly all AIDS-defining opportunistic infections (OIs) decreased significantly in the United States during 1992-1998; decreases in the most common OIs (Pneumocystis carinii pneumonia ¿PCP, esophageal candidiasis, and disseminated Mycobacterium avium complex ¿MAC disease) were more pronounced in 1996-1998, during which time highly active antiretroviral therapy (HAART) was introduced into medical care. Those OIs that continue to occur do so at low CD4+ T lymphocyte counts, and persons whose CD4+ counts have increased in response to HAART are at low risk for OIs, a circumstance that suggests a high degree of immune reconstitution associated with HAART. PCP, the most common serious OI, continues to occur primarily in persons not previously receiving medical care. The most profound effect on survival of patients with AIDS is conferred by HAART, but specific OI prevention measures (prophylaxis against PCP and MAC and vaccination against Streptococcus pneumoniae) are associated with a survival benefit, even when they coincide with the administration of HAART. Continued monitoring of incidence trends and detection of new syndromes associated with HAART are important priorities in the HAART era.

[1]  P. Pellett,et al.  Human herpesvirus 8 and Kaposi's sarcoma in persons infected with human immunodeficiency virus. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[2]  J. Ward,et al.  Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. Adult/Adolescent Spectrum of Disease Group. , 1999, AIDS.

[3]  H. Amandus,et al.  Adherence to guidelines for antiretroviral therapy and for preventing opportunistic infections in HIV-infected adults and adolescents in Ryan White-funded facilities in the United States. , 1999, Journal of acquired immune deficiency syndromes.

[4]  J A Fleishman,et al.  Variations in the care of HIV-infected adults in the United States: results from the HIV Cost and Services Utilization Study. , 1999, JAMA.

[5]  A. Telenti,et al.  The New England Jour nal of Medicine DISCONTINUATION OF PRIMARY PROPHYLAXIS AGAINST PNEUMOCYSTIS CARINII PNEUMONIA IN HIV-1–INFECTED ADULTS TREATED WITH COMBINATION ANTIRETROVIRAL THERAPY , 2022 .

[6]  A. Mocroft,et al.  Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection , 1999, The Lancet.

[7]  J. Ward,et al.  Surveillance for AIDS-defining opportunistic illnesses, 1992-1997. , 1999, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[8]  C. Jaspers,et al.  Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy , 1999, The Lancet.

[9]  J. Ward,et al.  Effect of antiretroviral therapy on recent trends in selected cancers among HIV-infected persons. Adult/Adolescent Spectrum of HIV Disease Project Group. , 1998, Journal of acquired immune deficiency syndromes.

[10]  D. McCaffrey,et al.  The care of HIV-infected adults in the United States. HIV Cost and Services Utilization Study Consortium. , 1998, The New England journal of medicine.

[11]  J. Akiyama Surveillance for waterborne-disease outbreaks--United States, 1995-1996. , 1998, MMWR. CDC surveillance summaries : Morbidity and mortality weekly report. CDC surveillance summaries.

[12]  B. Yip,et al.  The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[13]  JD Lundgren,et al.  Changing patterns of mortality across Europe in patients infected with HIV-1 , 1998, The Lancet.

[14]  F. Raffi,et al.  Opportunistic infections occurring during highly active antiretroviral treatment , 1998, AIDS.

[15]  T. Navin,et al.  Risk factors for primary Pneumocystis carinii pneumonia in human immunodeficiency virus-infected adolescents and adults in the United States: reassessment of indications for chemoprophylaxis. , 1998, The Journal of infectious diseases.

[16]  M. Woods,et al.  HIV combination therapy: partial immune restitution unmasking latent cryptococcal infection , 1998, AIDS.

[17]  J. Kahn,et al.  Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. , 1998, The New England journal of medicine.

[18]  J. Ward,et al.  Trends in AIDS-related opportunistic infections among men who have sex with men and among injecting drug users, 1991-1996. , 1998, The Journal of infectious diseases.

[19]  M. Narita,et al.  Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. , 1998, American journal of respiratory and critical care medicine.

[20]  B Clotet,et al.  Antiretroviral drug resistance testing in adults with HIV infection: implications for clinical management. International AIDS Society--USA Panel. , 1998, JAMA.

[21]  J. Oleske,et al.  Guidelines for the use of antiretroviral agents in pediatric HIV infection , 1998 .

[22]  G. Satten,et al.  Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. , 1998, The New England journal of medicine.

[23]  N. Letvin,et al.  Focal mycobacterial lymphadenitis following initiation of protease-inhibitor therapy in patients with advanced HIV-1 disease , 1998, The Lancet.

[24]  C. Beard,et al.  Opportunistic Infections (OIs) as Emerging Infectious Diseases: Challenges Posed by OIs in the 1990s and Beyond , 1998 .

[25]  W. Craig,et al.  Emerging Infections 2 , 1998 .

[26]  M. Jacobson,et al.  Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy , 1997, The Lancet.

[27]  M Gwinn,et al.  Prevalence of HIV infection in the United States, 1984 to 1992. , 1996, JAMA.

[28]  H. Barnhart,et al.  Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. , 1996, Pediatrics.

[29]  R. Chaisson,et al.  Natural History of Opportunistic Disease in an HIV-Infected Urban Clinical Cohort , 1996, Annals of Internal Medicine.

[30]  J. Neaton,et al.  Frequencies of opportunistic diseases prior to death among HIV‐infected persons , 1995, AIDS.

[31]  K. Holmes,et al.  USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with human immunodeficiency virus: introduction. USPHS/IDSA Prevention of Opportunistic Infections Working Group. , 1995, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[32]  J. Thornton Prevalence of HIV infection , 1995, BMJ.

[33]  J. Fleishman,et al.  Correlates of medical service utilization among people with HIV infection. , 1994, Health services research.

[34]  D. Follmann,et al.  Use of preventive interventions by persons infected with type-1 human immunodeficiency virus (HIV-1). The Pulmonary Complications of HIV Study Group. , 1994, American journal of preventive medicine.

[35]  R. Chaisson,et al.  Racial differences in the use of drug therapy for HIV disease in an urban community. , 1994, The New England journal of medicine.

[36]  K. Castro,et al.  Gender differences in reported AIDS-indicative diagnoses. , 1993, The Journal of infectious diseases.

[37]  J. Phair,et al.  Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the Multicenter AIDS Cohort Study: 1985-1991. , 1993, American journal of epidemiology.

[38]  C. Reed,et al.  Spectrum of disease in persons with human immunodeficiency virus infection in the United States. , 1992, JAMA.